Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
rogocekib（CTX-712）ocipumaltib（CTX-177）CTX-439GCN2 inhibitor
Applicable field (uses covered by this announcement)
Cancer research and development
Launch date7 May 2026 (broadcast date)
Relationship between the counterparty and the company
Chordia Therapeutics Inc.190A
Relationship with the Company
Program appearance and interview
CounterpartyNikkei Radio Broadcasting Corporation (Radio NIKKEI)
Location (as indicated in this announcement)
Fujisawa, Kanagawa Prefecture (head office)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Source (materials cited by the company)
Radio NIKKEI's “Market Terrace: Sakurai Hideaki Explores the True Faces of Business Leaders”
| Item | Details |
|---|---|
| Names of Products / Services Covered | rogocekib（CTX-712）, ocipumaltib（CTX-177）, CTX-439, GCN2 inhibitor |
| Counterparty | Nikkei Radio Broadcasting Corporation (Radio NIKKEI) |
| Relationship with the Company | Program appearance and interview |
| Launch date | 7 May 2026 (broadcast date) |
| Applicable area | Cancer research and development |
| Location | Fujisawa, Kanagawa Prefecture (head office) |
| Source | Radio NIKKEI's “Market Terrace: Sakurai Hideaki Explores the True Faces of Business Leaders” |
Items this document does not state (11)
Counterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative EffectsUsage historyImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To explain to investors and other stakeholders the Company's business overview, research and development initiatives, and key points concerning its future business operations.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.